Patents by Inventor Angelica Messana

Angelica Messana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240287453
    Abstract: The present disclosure features allogeneic modified immune cells (e.g., T- or NK-cells) having increased persistence, increased resistance to immune rejection, or decreased risk of eliciting a host-versus-graft reaction, or a combination thereof. Methods for producing and using the same are also provided.
    Type: Application
    Filed: February 14, 2024
    Publication date: August 29, 2024
    Applicant: Beam Therapeutics Inc.
    Inventors: Colby MALDINI, Angelica MESSANA, Jason Michael GEHRKE, Leila PERARO, Lauren YOUNG
  • Publication number: 20240132867
    Abstract: The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.
    Type: Application
    Filed: October 13, 2023
    Publication date: April 25, 2024
    Applicant: Beam Therapeutics Inc.
    Inventors: Nicole GAUDELLI, Michael PACKER, Ian SLAYMAKER, Yi YU, Bernd ZETSCHE, Jason Michael GEHRKE, Natalie PETROSSIAN, Angelica MESSANA, Yvonne ARATYN, Francine GREGOIRE, Genesis LUNG, Shaunna BERKOVITCH, David A. BORN, Seung-Joo LEE
  • Publication number: 20230140953
    Abstract: The invention provides compositions comprising novel programmable adenosine base editor systems (e.g., ABE8) that provide methods of treating a disease or disorder, (e.g., Parkinson's disease, Hurler syndrome, Rett syndrome, or Stargardt disease) in a subject by administering to the subject a programmable adenosine base editor system (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a disease-associated gene.
    Type: Application
    Filed: February 13, 2020
    Publication date: May 11, 2023
    Applicant: BEAM THERAPEUTICS INC.
    Inventors: Ian SLAYMAKER, Nicole GAUDELLI, Yi YU, Bernd ZETSCHE, David A. BORN, Seung-Joo LEE, Michael PACKER, Jason Michael GEHRKE, Natalie PETROSSIAN, Angelica MESSANA, Shaunna BERKOVITCH
  • Publication number: 20220313799
    Abstract: The present invention features compositions and methods for editing a gene associated with Shwachman Diamond Syndrome (SDS) using a programmable nucleobase editor, such that the gene is permissive for transcription and generates a functional gene product (e.g., providing a splice site and/or altering a nonsense mutation).
    Type: Application
    Filed: August 28, 2020
    Publication date: October 6, 2022
    Applicant: Beam Therapeutics Inc.
    Inventors: Jason Michael GEHRKE, Luis BARRERA, Angelica MESSANA
  • Publication number: 20220170027
    Abstract: The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 2, 2022
    Applicant: BEAM THERAPEUTICS INC.
    Inventors: Nicole GAUDELLI, Michael Michael PACKER, Ian SLAYMAKER, Yi YU, Bernd ZETSCHE, Jason Michael GEHRKE, Natalie PETROSSIAN, Angelica MESSANA, Yvonne ARATYN, Francine GREGOIRE, Genesis LUNG, Shaunna BERKOVITCH, David A. BORN, Seung-Joo LEE
  • Publication number: 20220098593
    Abstract: The invention features compositions and methods for treating, reducing, or ameliorating the debilitating effects of Amyotrophic Lateral Sclerosis (ALS) and spinal and bulbar muscular atrophy (SBMA). Provided herein are compositions and methods of using improved new base editors (e.g., adenosine base editors) comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain in conjunction with a guide polynucleotide to disrupt normal transcription of a gene associated with a genetic disease or condition, e.g. ALS, or SBMA by modifying a target gene associated with the genetic disorder or condition with a base editor system provided herein.
    Type: Application
    Filed: February 13, 2020
    Publication date: March 31, 2022
    Applicant: BEAM THERAPEUTICS INC.
    Inventors: Nicole GAUDELLI, Michael PACKER, Ian SLAYMAKER, Yi YU, Bernd ZETSCHE, Jason Michael GEHRKE, Angelica MESSANA, David A. BORN, Seung-Joo LEE
  • Patent number: 11155803
    Abstract: The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: October 26, 2021
    Assignee: BEAM THERAPEUTICS INC.
    Inventors: Nicole Gaudelli, Michael Packer, Ian Slaymaker, Yi Yu, Bernd Zetsche, Jason Michael Gehrke, Natalie Petrossian, Angelica Messana, Yvonne Aratyn, Francine Gregoire, Genesis Lung, Shaunna Berkovitch, David A. Born, Seung-Joo Lee
  • Publication number: 20210130805
    Abstract: The disclosure provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using these adenosine deaminase variants for editing a target sequence.
    Type: Application
    Filed: December 18, 2020
    Publication date: May 6, 2021
    Applicant: Beam Therapeutics Inc.
    Inventors: Nicole GAUDELLI, Michael PACKER, Ian SLAYMAKER, Yi YU, Bernd ZETSCHE, Jason Michael GEHRKE, Natalie PETROSSIAN, Angelica MESSANA, Yvonne ARATYN, Francine GREGOIRE, Genesis LUNG, Shaunna BERKOVITCH, David A. BORN, Seung-Joo LEE
  • Publication number: 20170320998
    Abstract: The present invention relates to curable polyurethane polymers made from renewable materials. In particular hydroxylated oleaginous materials derived from plant oils, such as soybean oil, are used. These renewable materials may be formed into curable polyurethane polymers having different chemical functionalities and cure mechanisms.
    Type: Application
    Filed: July 26, 2017
    Publication date: November 9, 2017
    Inventors: Andrew D. Messana, David P. Dworak, Anthony F. Jacobine, Angelica Messana
  • Patent number: 9587151
    Abstract: The invention provides anaerobic curable compositions comprising a (meth)acrylate component, at least a portion which comprises a (meth)acrylate-functionalized bio-renewable oleaginous polyurethane polymer, and methods of their production and use. These compositions provide excellent adhesion especially on oily surfaces.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: March 7, 2017
    Assignee: Henkel IP & Holding GmbH
    Inventors: Andrew D. Messana, David P. Dworak, Angelica Messana, Anthony F. Jacobine, Darel Gustafson
  • Publication number: 20150136323
    Abstract: The invention provides anaerobic curable compositions comprising a (meth)acrylate component, at least a portion which comprises a (meth)acrylate-functionalized bio-renewable oleaginous polyurethane polymer, and methods of their production and use. These compositions provide excellent adhesion especially on oily surfaces.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 21, 2015
    Inventors: Andrew D. Messana, David P. Dworak, Angelica Messana, Anthony F. Jacobine, Darel Gustafson